Rodman & Renshaw Launches DirectMarkets: First-Ever 24/7 Automated Electronic Transaction Platform
Rodman & Renshaw Capital Group, Inc. will unveil an automated state-of-the-art electronic transaction platform to directly link issuers and investors.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
TDI-132 shows promising results in the treatment of ALS
ALS may be the most deadly disease many people have never heard of. Also referred to as Lou Gehrig’s disease, it affects at least 30,000 people in the United States and 450,000 people worldwide.
Editor’s Note March 6, 2012
Spring is on it’s way and things are heating up as well in the healthcare and life science industry. In this week’s Sentinel: Kevin Lupowitz […]
Producer of Advamed 2012, Ray Briscuso Leads One of The Largest MedTech Conferences in a New Direction
AdvaMed 2012, the big medtech conference for industry executives, has launched its website and is calling for proposals for program panels.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
“Inside the FDA” session at BIO CEO Addressed PDUFA and TREAT Acts
This is one of the largest sources of frustration currently among health care companies and investors.
This Week in Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
BIO CEO & Investor Conference Has Grown in Size and Offered Insight on Industry Mood
According to BIO’s statistics, “a majority of investors (56%) still think now is a good time to invest.